UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support
September 2nd 1997Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral